Piper Sandler Maintains Overweight on Conmed, Lowers Price Target to $68

Benzinga · 07/31/2025 13:55
Piper Sandler analyst Matt O'Brien maintains Conmed (NYSE:CNMD) with a Overweight and lowers the price target from $80 to $68.